Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Icon ( (ICLR) ) just unveiled an update.
In its financial results for the fourth quarter and full year of 2024, ICON plc reported net business wins of $2,413 million for the quarter and $9,974 million for the year, with a backlog increase of 8.3% from the previous year. While the fourth quarter revenue decreased by 1.2% from the prior year, the full year revenue saw a 2.0% increase, alongside a 9.5% growth in adjusted diluted earnings per share. The company also announced a new share repurchase program of up to $750 million, reflecting its strong cash management and strategic financial positioning.
More about Icon
ICON plc is a leading healthcare intelligence and clinical research organization. The company offers outsourced services to the pharmaceutical, biotechnology, medical device, and government sectors, advancing clinical research from molecule to medicine.
YTD Price Performance: -11.28%
Average Trading Volume: 1,008,362
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $15.57B
Learn more about ICLR stock on TipRanks’ Stock Analysis page.
